European Commission Expands Merck's ERVEBO [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved an expanded indication for Merck's ERVEBO vaccine, allowing its use for active immunization of individuals 1 year of age or older against Ebola Virus Disease. Previously, the vaccine was approved for use in the European Union for individuals 18 years of age or older.
September 07, 2023 | 10:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The expanded approval of Merck's ERVEBO vaccine by the European Commission could potentially increase the company's revenue as it broadens the vaccine's target demographic.
The European Commission's approval to expand the use of Merck's ERVEBO vaccine to individuals 1 year of age or older increases the potential market for the vaccine. This could lead to increased sales and revenue for Merck, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100